Edmond M. Kwan - Concepedia

Author

Edmond M. Kwan

Also Known As

E. Kwan, E. M. Kwan, E.M. Kwan, EDMOND MICHAEL KAM MING KWAN, Edmon M. Kwan, Edmond Kwan, Edmond M Kwan, Edmond M. Kwan, Edmond Michael Kwan, KWAN, EDMOND MICHAEL KAM MING

241

Publications

2.9K

Citations

H-Index

Concepts

All Affiliations

Monash University Peter MacCallum Cancer Centre Monash Health The University of Melbourne Eastern Health

About

Edmond M. Kwan is an author at Monash University specializing in medicine, oncology, and radiation oncology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	13	14	1.7K
2	Health Sciences	1	1	40
3	Public Health	1	1	12
4	Epidemiology	1	1	12
5	Genomic Medicine	1	1	12

Edmond M. Kwan

Publications

2.6K

Citations

H-Index

Page 1

	Year	Citations
[177Lu]Lu-PSMA-617 versus cabazitaxel in patients with metastatic castration-resistant prostate cancer (TheraP): a randomised, open-label, phase 2 trial Michael S. Hofman, Louise Emmett, Shahneen Sandhu, The Lancet UrologyOncologyGenitourinary CancerMedicineClinical Trials	2021	1K
PSMA and FDG-PET as predictive and prognostic biomarkers in patients given [177Lu]Lu-PSMA-617 versus cabazitaxel for metastatic castration-resistant prostate cancer (TheraP): a biomarker analysis from a randomised, open-label, phase 2 trial James P Buteau, Andrew Martin, Louise Emmett, The Lancet Oncology Biomarker (Medicine)Prognostic BiomarkersUrologyOncologyBiomarker Analysis	2022	239
Overall survival with [177Lu]Lu-PSMA-617 versus cabazitaxel in metastatic castration-resistant prostate cancer (TheraP): secondary outcomes of a randomised, open-label, phase 2 trial Michael S. Hofman, Louise Emmett, Shahneen Sandhu, The Lancet Oncology UrologyOverall SurvivalGenitourinary CancerMedicineCancer Management	2023	172
Clinical and genomic insights into circulating tumor DNA-based alterations across the spectrum of metastatic hormone-sensitive and castrate-resistant prostate cancer Manish Kohli, Winston Tan, Tiantian Zheng, EBioMedicine	2020	131
Prediction of plasma ctDNA fraction and prognostic implications of liquid biopsy in advanced prostate cancer Nicolette M. Fonseca, Corinne Maurice‐Dror, Cameron Herberts, Nature Communications	2024	101
The MURAL collection of prostate cancer patient-derived xenografts enables discovery through preclinical models of uro-oncology Gail P. Risbridger, Ashlee K. Clark, Laura H. Porter, Nature Communications	2021	66
Avelumab Combined with Stereotactic Ablative Body Radiotherapy in Metastatic Castration-resistant Prostate Cancer: The Phase 2 ICE-PAC Clinical Trial Edmond M. Kwan, Lavinia Spain, A. Antón, European Urology Ice-pac Clinical TrialSurgical OncologyUrologyRadiation TherapyMedicine	2021	65
Combined Cell-free DNA and RNA Profiling of the Androgen Receptor: Clinical Utility of a Novel Multianalyte Liquid Biopsy Assay for Metastatic Prostate Cancer Heidi Fettke, Edmond M. Kwan, Maria Docanto, European Urology Androgen ReceptorUrologyGenitourinary CancerMedicineBiomarker Target	2020	59
Detection of ctDNA in plasma of patients with clinically localised prostate cancer is associated with rapid disease progression Edmund Lau, Patrick J. McCoy, Fairleigh Reeves, Genome Medicine	2020	56
Nivolumab plus rucaparib for metastatic castration-resistant prostate cancer: results from the phase 2 CheckMate 9KD trial Karim Fizazi, Margitta Retz, Daniel P. Petrylak, Journal for ImmunoTherapy of Cancer	2022	51

Page 1